Mar­tin Shkre­li is back in the crosshairs of the fed­er­al gov­ern­ment for not stay­ing out of phar­ma

Mar­tin Shkre­li made a name for him­self for goug­ing the price of Dara­prim by 4,000%, say­ing he should’ve raised it even high­er, and then fac­ing an ex­pect­ed back­lash from both Con­gress and the courts over his greed. The re­sult: a life­time ban from the phar­ma in­dus­try and a $65 mil­lion fine.

Now, the Fed­er­al Trade Com­mis­sion said to­day in a court fil­ing in the south­ern dis­trict of New York that Shkre­li is vi­o­lat­ing that ban by fail­ing to pay his fine and by form­ing a new com­pa­ny, called “Drug­like, Inc.,” which claims to be in­volved in “ear­ly stage drug dis­cov­ery.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER